Economic Atlas
Companies/VYNE Therapeutics Inc.
Company profile

VYNE Therapeutics Inc.

NASDAQ: VYNE · Healthcare · Biotechnology
PublicHQ Bridgewater, NJCIK 0001566044Reports USD
#930 of 1,422 Healthcare companies by revenue60th-percentile growth
EA Score
38D
Revenue TTM
$454.0k
Rev growth YoY (TTM)
-25.0%
Net income (FY)
-$26.5M
Employees
10
as of 2026-08-22
Market cap
$19.1M
as of 2026-08-22

Financials — latest annual

SEC EDGAR · USD-normalized
ConceptUSDNativeFY
Revenue$570.0k$570.0k2025
Net income-$26.5M-$26.5M2025
Operating income-$29.7M-$29.7M2025
Total assets$30.2M$30.2M2025
Liabilities$2.4M$2.4M2025
Equity$27.8M$27.8M2025

Revenue trend

FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25

Revenue by segment

Filed disclosures · FY2025
By product
Reportable100%
By geography

Not disclosed.

The read

What is VYNE Therapeutics Inc.’s revenue?

VYNE Therapeutics Inc. booked $570.0k in FY2025 revenue, growing 14% year over year — faster than most Healthcare companies we track, at a -4646.1% net margin.

Peers · Healthcare
Theralase Technologies Inc.37DErnexa Therapeutics Inc.43DViropro Inc.——Trevena, Inc.——Solana Company49DCardax, Inc.——
Key facts
CEODavid T. Domzalski
SectorHealthcare
IndustryBiotechnology
HeadquartersBridgewater, NJ
ExchangeNASDAQ: VYNE
Employees10
IPO date2018-01-25
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.